Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavß in patients with advanced solid tumours

Ferry Eskens, H Dumez, R (Rosa) Hoekstra, A Perschl, CJ Brindley, S Böttcher, W Wynendaele, J Drevs, Jaap Verweij, AT van Oosterom

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)917-926
Number of pages10
JournalEuropean Journal of Cancer
Volume39
DOIs
Publication statusPublished - 2003

Cite this